NuVasive Unveils New Trauma Portfolio And Virtual Reality Simulation At AANS 2017

SAN DIEGO, CA – April 20, 2017 – NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced it will showcase the Company’s new RELINE® Trauma portfolio and O.R. virtual reality (VR) simulation at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting held April 22-26, 2017 in Los Angeles.

Launched earlier this week, RELINE Trauma will help define the standard of spine trauma care by providing surgeons the flexibility to customize their approach intra-operatively, including traditional open, MAS® (Maximum Access Surgery) or hybrid procedures, depending on the pathology and patient needs. Seamlessly integrated with the Company’s Integrated Global Alignment® (iGA) platform, RELINE Trauma allows for controlled fracture correction throughout the procedure, with or without a rod present in the construct.

“RELINE Trauma is the most versatile trauma system on the market,” said Jason Hannon, NuVasive’s president and chief operating officer. “In collaboration with our surgeon partners, we’ve succeeded in creating a platform designed not only to improve clinical outcomes, but also to reduce the total cost of care.”

Additionally, NuVasive will showcase an immersive VR experience designed to familiarize surgeons with the techniques of the RELINE Trauma system. The VR simulation provides step-by-step instruction of the procedure, while helping develop the associated muscle memory required to address a burst fracture in an interactive O.R. setting.

NuVasive 2017 AANS Annual Scientific Meeting Participation Details

NuVasive will showcase its market-leading, procedurally-integrated technologies, including the new RELINE Trauma system and VR experience at NuVasive Booth #1327 on the AANS Annual Scientific Meeting exhibit floor.

The Company also will host a lunch and learn workshop presented by Regis Haid, M.D., Christopher Shaffrey, M.D., and Juan Uribe, M.D., titled “Advanced Techniques in Achieving Integrated Spinal Alignment” on April 24, 2017 from 1:10 p.m. to 1:55 p.m. in room 309.

Visit here for more details and schedule of events.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

# # #

Investor Contact:
Suzanne Hatcher
NuVasive, Inc.
858-458-2240
investorrelations@nuvasive.com

 

Media Contact:
Stefanie Mazer
NuVasive, Inc.
858-320-5243
media@nuvasive.com

Previous PostNext Post